Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Literature
1.
Markman M (2003) Managing taxane toxicities. Support Care Cancer 11:144–147PubMed
2.
Kautio AL, Haanpaa M, Kautiainen H, Kalso E, Saarto T (2011) Burden of chemotherapy-induced neuropathy—a cross-sectional study. Support Care Cancer 19:1991–1996PubMedCrossRef
3.
Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646–662PubMed
4.
Webster LK, Crinis NA, Morton CG, Millward MJ (1996) Plasma alcohol concentrations in patients following paclitaxel infusion. Cancer Chemother Pharmocol 37:499–501CrossRef
5.
Meng S, Su B, Li W, Ding Y, Tang L, Zhou W, Song Y, Caicun Z (2011) Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol 28:1180–1187PubMedCrossRef
Metadata
Title
Drug-induced hallucinatory syndrome in a patient with breast cancer after paclitaxel infusion
Authors
L. Slovacek
B. Slovackova
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1438-3

Other articles of this Issue 9/2012

Supportive Care in Cancer 9/2012 Go to the issue

Original Article

Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction

Original Article

Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study

Short Communication

A new palliative care consultation team at the oncology department of a university hospital: an assessment of initial efficiency and effectiveness

Original Article

Swallowing, nutrition and patient-rated functional outcomes at 6 months following two non-surgical treatments for T1–T3 oropharyngeal cancer

Original Article

Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review

Original Article

Evaluating adherence to recommended diets among cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits